Jida Mouhamad, Sanchez Cecilia P, Urgin Karène, Ehrhardt Katharina, Mounien Saravanan, Geyer Aurelia, Elhabiri Mourad, Lanzer Michael, Davioud-Charvet Elisabeth
UMR 7509 Centre National de la Recherche Scientifique and University of Strasbourg, European School of Chemistry, Polymers and Materials (ECPM) , 25 rue Becquerel, F-67087 Strasbourg, France.
Zentrum für Infektiologie, Parasitologie, Universität Heidelberg , Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.
ACS Infect Dis. 2017 Feb 10;3(2):119-131. doi: 10.1021/acsinfecdis.5b00141. Epub 2016 Dec 7.
Mutational changes in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) have been associated with differential responses to a wide spectrum of biologically active compounds including current and former quinoline and quinoline-like antimalarial drugs. PfCRT confers altered drug responsiveness by acting as a transport system, expelling drugs from the parasite's digestive vacuole where these drugs exert, at least part of, their antiplasmodial activity. To preserve the efficacy of these invaluable drugs, novel functional tools are required for epidemiological surveys of parasite strains carrying mutant PfCRT variants and for drug development programs aimed at inhibiting or circumventing the action of PfCRT. Here we report the synthesis and characterization of a pH-sensitive fluorescent chloroquine analogue consisting of 7-chloro-N-{2-[(propan-2-yl)amino]ethyl}quinolin-4-amine functionalized with the fluorochrome 7-nitrobenzofurazan (NBD) (henceforth termed Fluo-CQ). In the parasite, Fluo-CQ accumulates in the digestive vacuole, giving rise to a strong fluorescence signal but only in parasites carrying the wild type PfCRT. In parasites carrying the mutant PfCRT, Fluo-CQ does not accumulate. The differential handling of the fluorescent probe, combined with live cell imaging, provides a diagnostic tool for quick detection of those P. falciparum strains that carry a PfCRT variant associated with altered responsiveness to quinoline and quinoline-like antimalarial drugs. In contrast to the accumulation studies, chloroquine (CQ)-resistant parasites were observed cross-resistant to Fluo-CQ when the chemical probe was tested in various CQ-sensitive and -resistant parasite strains. NBD derivatives were found to act as redox cyclers of two essential targets, using a coupled assay based on methemoglobin and the NADPH-dependent glutathione reductase (GRs) from P. falciparum. This redox activity is proposed to contribute to the dual action of Fluo-CQ on redox equilibrium and methemoglobin reduction via PfCRT-mediated drug efflux in the cytosol and then continuous redox-dependent shuttling between food vacuole and cytosol. Taking into account these physicochemical characteristics, a model was proposed to explain Fluo-CQ antimalarial effects involving the contribution of PfCRT-mediated transport, methemoglobin reduction, hematin binding, and NBD reduction activity catalyzed by PfGR in CQ-resistant versus CQ-sensitive parasites. Therefore, introduction of NBD fluorophore in drugs is not inert and should be taken into account in drug transport and imaging studies.
恶性疟原虫氯喹抗性转运蛋白(PfCRT)的突变变化与对多种生物活性化合物的不同反应有关,这些化合物包括现有的和以前的喹啉及喹啉类抗疟药物。PfCRT作为一种转运系统发挥作用,将药物从寄生虫的消化液泡中排出,而这些药物至少部分地在消化液泡中发挥其抗疟活性,从而导致药物反应性改变。为了保持这些极其重要药物的疗效,需要新的功能工具来对携带突变PfCRT变体的寄生虫菌株进行流行病学调查,并用于旨在抑制或规避PfCRT作用的药物开发项目。在此,我们报告了一种对pH敏感的荧光氯喹类似物的合成与表征,该类似物由用荧光染料7-硝基苯并呋咱(NBD)功能化的7-氯-N-{2-[(丙-2-基)氨基]乙基}喹啉-4-胺组成(以下简称Fluo-CQ)。在寄生虫中,Fluo-CQ在消化液泡中积累,仅在携带野生型PfCRT的寄生虫中产生强烈的荧光信号。在携带突变型PfCRT的寄生虫中,Fluo-CQ不积累。荧光探针的这种不同处理方式,结合活细胞成像,为快速检测那些携带与对喹啉和喹啉类抗疟药物反应性改变相关的PfCRT变体的恶性疟原虫菌株提供了一种诊断工具。与积累研究相反,当在各种对氯喹敏感和耐药的寄生虫菌株中测试这种化学探针时,观察到对氯喹(CQ)耐药的寄生虫对Fluo-CQ也具有交叉耐药性。基于恶性疟原虫的高铁血红蛋白和NADPH依赖性谷胱甘肽还原酶(GRs)的偶联测定发现,NBD衍生物可作为两个重要靶点的氧化还原循环剂。这种氧化还原活性被认为有助于Fluo-CQ通过PfCRT介导的药物外排在细胞质中对氧化还原平衡和高铁血红蛋白还原的双重作用,然后在食物液泡和细胞质之间进行连续的氧化还原依赖性穿梭。考虑到这些物理化学特性,提出了一个模型来解释Fluo-CQ的抗疟作用,该作用涉及PfCRT介导的转运、高铁血红蛋白还原、血红素结合以及PfGR在对CQ耐药与对CQ敏感的寄生虫中催化的NBD还原活性的贡献。因此,在药物中引入NBD荧光团并非是惰性的,在药物转运和成像研究中应予以考虑。